Evaluation of CD3+CD56+ NKT and CD19+ B Cells in Assessing the Relapse of Neuromyelitis Optica Spectrum Disorder Patients Treated With Rituximab
Sign Up to like & getrecommendations! Published in 2025 at "Brain and Behavior"
DOI: 10.1002/brb3.70950
Abstract: The purpose of this study was to explore the value of pre‐treatment levels of CD3+CD56+ NKT cells and CD19+ B cells in evaluating the relapse of patients with neuromyelitis optica spectrum disorders (NMOSD) treated with… read more here.
Keywords: cd19 cells; neuromyelitis optica; treated rituximab; optica spectrum ... See more keywords
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology International"
DOI: 10.1007/s00296-020-04699-x
Abstract: The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2… read more here.
Keywords: patients treated; disease; sars cov; treated rituximab ... See more keywords
PROLONGED COVID-19 IN PATIENTS TREATED WITH RITUXIMAB
Sign Up to like & getrecommendations! Published in 2021 at "Chest"
DOI: 10.1016/j.chest.2021.07.297
Abstract: TOPIC: Chest Infections TYPE: Fellow Case Reports INTRODUCTION: Patients with COVID-19 who have been prescribed rituximab prior to SARS-CoV-2 infection may be susceptible to an alternative disease course compared to the general population. These patients… read more here.
Keywords: therapy; infection; rituximab prior; prolonged covid ... See more keywords
Linear IgA bullous dermatosis treated with rituximab
Sign Up to like & getrecommendations! Published in 2019 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2018.11.004
Abstract: LABD: Linear IgA bullous dermatosis MMF: mycophenolate mofetil L inear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disease with an incidence of 0.5 cases per million inhabitants per year. Pathogenic IgA autoantibodies mostly… read more here.
Keywords: bullous dermatosis; treated rituximab; labd; iga bullous ... See more keywords
Evaluating the risk‐to‐benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: A retrospective study with 494 patients
Sign Up to like & getrecommendations! Published in 2021 at "Dermatologic Therapy"
DOI: 10.1111/dth.15257
Abstract: Rituximab is widely used as the first‐line treatment for pemphigus patients. Since it depletes the B cells, it increases the risk of infections. Here, we evaluated the prophylactic efficacy of cotrimoxazole in decreasing the risk… read more here.
Keywords: 494 patients; pemphigus patients; risk; patients treated ... See more keywords
Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14144
Abstract: Rituximab is an effective treatment for pemphigus and can be considered as a first-line treatment for severe cases.1-4 Rituximab increases the risk of infection with Pneumocystis jiroveci pneumonia (PJP), an opportunistic pathogen, especially in hematopoietic… read more here.
Keywords: infection; jiroveci pneumonia; infection pneumocystis; treated rituximab ... See more keywords
Nocardiosis in systemic lupus erythematosus patients treated with rituximab: Report of two cases and systematic review of literature
Sign Up to like & getrecommendations! Published in 2025 at "Lupus"
DOI: 10.1177/09612033251319836
Abstract: Background The relationship between systemic lupus erythematosus (SLE) patients treated with rituximab and nocardiosis remains unclear. Cases Report A 55-year-old female with lupus nephritis II and smoking history, was treated with high-dose steroids, immunoglobulins, rituximab,… read more here.
Keywords: lupus; treated rituximab; systemic lupus; patients treated ... See more keywords
Rituximab for Adults With Multi-Drug Resistant Focal Segmental Glomerulosclerosis: A Case Series and Review of the Literature
Sign Up to like & getrecommendations! Published in 2022 at "Canadian Journal of Kidney Health and Disease"
DOI: 10.1177/20543581221090010
Abstract: Background: Adults with primary focal segmental glomerulosclerosis (FSGS) are frequently resistant to multiple immunosuppressive agents, which is associated with ongoing complications of nephrotic syndrome and a high risk of progression to end-stage renal disease (ESRD).… read more here.
Keywords: treated rituximab; review; case series; literature ... See more keywords
Increased C-Reactive Protein Level Is Associated with Poor Prognosis in Patients with Follicular Lymphoma Treated with Rituximab-Containing Regimens
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.4067.4067
Abstract: Introduction: C-reactive protein (CRP) is a useful inflammatory marker in clinical practice. It is a prognostic factor in several types of tumors, including diffuse large B cell lymphoma (DLBCL) and extranodal natural killer/T-cell lymphoma, nasal… read more here.
Keywords: elevated crp; containing regimens; associated poor; rituximab containing ... See more keywords